Transaction deepens insights into Sec61 selectivity for targeted protein degradation, supporting accelerated development of Enodia’s novel small-molecule inhibitors PARIS & SOUTH SAN FRANCISCO, Calif.

The alternative text for this image may have been generated using AI. Taken together, when engaged in translocation of a hydrophilic nascent peptide, the Sec61 complex can adopt a conformation with a ...

French biotech Enodia Therapeutics is paying $1 million upfront in a backloaded deal for Kezar Life Sciences’ preclinical protein degradation program. The deal centers on Kezar’s almost decade-long ...

Sec61 is a critical component of the protein translocation machinery that mediates the entry of most secreted and transmembrane proteins into the endoplasmic reticulum. Sec61 has been proposed as a ...

Kezar Life Sciences ( (KZR)) has provided an announcement. On March 6, 2026, Kezar Life Sciences agreed to sell its Sec61-based discovery and development program, including preclinical candidate ...

Multiple myeloma is a cancer of the bone marrow, with a life expectancy of less than 5 years post-diagnosis. Proteasome inhibitors, the therapeutic backbone of current treatments, are very effective ...

Transaction deepens insights into Sec61 selectivity for targeted protein degradation, supporting accelerated development of Enodia’s novel small-molecule inhibitors “Kezar has made significant early ...

Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, and Kezar Life Sciences, Inc. (Nasdaq: KZR), a ...